Jon Hamilton

Scientists mapped the 548,000 connections in the brain of a fruit fly larva, but they're far from repeating the feat with a grown fruit fly. (Story aired on All Things Considered on Feb. 9, 2023.)

Researchers have mapped the more than 500,000 connections in the intricate brain of a fruit fly larva. This map, they say, could help scientists figure out how learning changes the human brain, too.

Two stroke patients regained control of a disabled arm and hand after researchers delivered electrical stimulation to their spines, paving the way toward a medical device that could aid movement.

For people with drug-resistant epilepsy, surgery used to be seen as a last resort. Now it's often the treatment of choice.

A man with uncontrolled epileptic seizures sought surgery in 2009, but was turned down. Ten years later, advances in neurodiagnostic testing, lasers and microelectronics finally helped him.

A study involving prairie voles shows that oxytocin may not live up to its billing as a "love hormone" that is essential to forming enduring attachments with mates.

The hormone oxytocin plays a key role in long-term relationships. But a study of prairie voles finds that the animals mate for life even without help from the "love hormone."

The Food and Drug Administration has approved an Alzheimer's drug that appears to modestly slow down the disease. (Story aired on Weekend Edition Saturday on Jan. 6, 2023.)

An Alzheimer's drug that removes the substance amyloid from the brain has received a conditional approval from the FDA. A large study found the drug decreased the loss of thinking and memory by 27%.

Psychedelic drugs were a hot topic at this year's Society for Neuroscience meeting. Researchers hope the drugs can help people with disorders like depression and PTSD.

The brain uses special neurons called time cells to organize our memories of events and experiences. But, despite their name, these cells don't work like a clock.

Researchers say the experimental Alzheimer's drug Lecanemab represents an important advance and is likely to get FDA approval in 2023, despite some safety concerns.

The experimental drug lecanemab was able to slow down Alzheimer's in a large study. Many researchers think the drug will become the first to help large numbers of patients.

Researchers say the experimental Alzheimer's drug Lecanemab represents an important advance and is likely to get FDA approval in 2023, despite some safety concerns.

An experimental drug appears to slow memory loss. Researchers say people with early Alzheimer's who got the drug for 18 months experienced 27% less cognitive decline than people who got a placebo.

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Over 23,000 neuroscientists gathered in San Diego last week to hear the latest discoveries on how the brain works.

Researchers are launching a make-or-break study to test the conventional wisdom about what causes Alzheimer's disease.

In a recent small study, the antidepressant effects of ketamine lasted longer when an intravenous dose was followed with computer games featuring smiling faces or words aimed at boosting self-esteem.

A dish of brain cells learned to play the 1970s video game Pong. The research could help computers become more intelligent